| Patents for A61P 1 - Drugs for disorders of the alimentary tract or the digestive system (125,798) |
|---|
| 02/09/2005 | CN1188055C Composition |
| 02/08/2005 | US6852889 Antioxidant nitroxides and nitrones as therapeutic agents |
| 02/08/2005 | US6852863 Osteoporosis; immunosuppressants; wound healing agent |
| 02/08/2005 | US6852751 Difluorobutyric acid metalloprotease inhibitors |
| 02/08/2005 | US6852749 Pyrazolidinol compounds |
| 02/08/2005 | US6852740 Treating p38 kinase mediated disorders. Compounds of particular interest are defined by Formula I Mitogen-activated protein kinases (MAP) is a family of proline- directed serine/threonine kinases that activate their |
| 02/08/2005 | US6852738 Potent ligands for PPAR gamma and generally have antagonist or partial agonist activity. The compoundsare for treatment, control or prevention of obesity, non-insulin dependent diabetes mellitus (NIDDM), hyperglycemia, dyslipidemia, |
| 02/08/2005 | US6852736 Phenoxypropanolamines, preparation and therapeutic use thereof |
| 02/08/2005 | US6852732 A tetrahydropyridino or piperidino heterocyclic derivative represented by the formula (I): has a high affinity for CRF receptors and is effective against diseases in which CRF is considered to be involved. (Corticotropin releasing factor |
| 02/08/2005 | US6852726 Such as 1-(4,5-dihydro-1H-imidazol-2-ylmethyl)-3-methanesulfonyl-2-methyl-1H-indole for preventing/treating disorders modulated by alpha-1A/L adrenoceptors such as urinary incontinence and sexual disorders |
| 02/08/2005 | US6852725 Imidazolyl derivatives |
| 02/08/2005 | US6852722 Administering a growth hormone secretagogue. |
| 02/08/2005 | US6852720 Thiazol-2-yl-imine compounds as PDE-7 inhibitors |
| 02/08/2005 | US6852717 Inhibit the release of inflammatory cytokines such as interleukin-1 and tumor necrosis factor; for use in therapy of diseases and pathological conditions involving inflammation such as chronic inflammatory disease |
| 02/08/2005 | US6852714 (Benzodioxan, benzofuran or benzopyran) derivatives having fundic relaxation properties |
| 02/08/2005 | US6852518 Glycosyl sulfotransferases GST-4α, GST-4β, and GST-6 |
| 02/08/2005 | CA2097208C The sulphate salt of a substituted triazole, pharmaceutical compositions thereof, and their use in therapy |
| 02/03/2005 | WO2005009992A1 Cyclohexanecarboxylic acid compound |
| 02/03/2005 | WO2005009454A1 Periodontal disease therapeutic and/or preventive composition |
| 02/03/2005 | WO2005009445A1 A1 adenosine receptor antagonists |
| 02/03/2005 | WO2005009427A1 Curative medicine for allergosis |
| 02/03/2005 | WO2005009331A2 Use of a cosmetic or pharmaceutical composition, comprising a lupeol-rich extract as an active ingredient for stimulating the synthesis of heat shock proteins |
| 02/03/2005 | WO2004098599A3 Proton pump inhibitors for the treatment of lower abdominal disorders |
| 02/03/2005 | WO2004089333A3 A stable benzimidazole formulation |
| 02/03/2005 | WO2003094859A3 Epha2 monoclonal antibodies and methods of use thereof |
| 02/03/2005 | WO2003062390A3 Compositions and methods for the modulation of sphingolipid metabolism and/or signaling |
| 02/03/2005 | WO2002096360A3 Single amino acid based compounds for counteracting effects of reactive oxygen species and free radicals |
| 02/03/2005 | US20050027121 Heterocyclic carboxy amines such as (2R)-1-[3,5-Bis(trifluoromethyl)benzoyl]-4-[4-((3S)-3-ethylmorpholino)-2-butynyl]-2-[(1H-indol-3-yl)methyl]piperazine, used as substance P and neurokinin antagonist for prophylaxis of diseases |
| 02/03/2005 | US20050027114 Methods and materials relating to cd84-like polypeptides and polynucleotides |
| 02/03/2005 | US20050027017 Rhinologically active substances |
| 02/03/2005 | US20050027016 Polyamine compounds and compositions for use in conjection with cancer therapy |
| 02/03/2005 | US20050027013 LTA4 hydrolase inhibitors |
| 02/03/2005 | US20050027009 New derivatives of N-(iminomethyl)amines, their preparation, their use as medicaments and the pharmaceutical compositions containing them |
| 02/03/2005 | US20050026990 N-[(3S)-1-hydroxy-2-oxopyrrolidinyl]-N-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-4-sulfonamide or derivatives to treat Respiratory system disorders; arthritis, and bone disorders |
| 02/03/2005 | US20050026988 Cyclopenta'b! indole derivatives as spla inhibitors |
| 02/03/2005 | US20050026981 Stable oral solid drug composition |
| 02/03/2005 | US20050026973 New heterocyclic oxime compounds |
| 02/03/2005 | US20050026967 Inhibitors of c-jun N terminal kinases (JNK) and other protein kinases |
| 02/03/2005 | US20050026942 Chemokine receptor binding heterocyclic compounds |
| 02/03/2005 | US20050026941 preferential inhibitors of cyclic guanosine 3',5'-monophosphate specific phosphodiesterase used for prophylaxis of erectile dysfunction and cardiovascular disorders |
| 02/03/2005 | US20050026934 Dissolved in water; recrystallized, dehydrated; lymphadenopathy associated virus, human T-cell leukemia/lymphoma virus, hepatitis virus |
| 02/03/2005 | US20050026926 N, N'-disubstituted piperazine compounds and their use as analgesics |
| 02/03/2005 | US20050026915 As melanin concentrating hormone (MCH)receptor antagonists, for prevention or treatment of obesity or eating disorders; (2E)-3-(4-chlorophenyl)-N-[2-(dimethylamino)quinolin-6-yl]prop-2-enamide |
| 02/03/2005 | US20050026908 Can bind to Prostaglandin E2 receptors, especially, EP3 receptor and/or EP4 receptor and show antagonizing activity, and may be useful for prevention and/or treatment of disease, for example, pain, allergy, Alzheimer's disease, cancer |
| 02/03/2005 | US20050026904 Cathepsin S, K, F, L and B reversible inhibitory amidino and guanidino peptidyl compounds useful for treating autoimmune diseases, rheumatoid arthritis, multiple sclerosis, asthma and osteoporosis |
| 02/03/2005 | US20050026875 Treating bacterial, viral, or fungal infections, cancer, a lung injury, an eye disorder, neurological disorder or stroke |
| 02/03/2005 | US20050026835 Methods of treating non-inflammatory gastrointestinal tract disorders using Cav2.2 subunit calcium channel modulators |
| 02/03/2005 | US20050026828 Methods for modulating gastric secretion using prokineticin receptor antagonists |
| 02/03/2005 | US20050026822 Human 3 relaxin |
| 02/03/2005 | US20050026268 Phytase from Bacillus subtilis, gene encoding said phytase, method for its production and use |
| 02/03/2005 | US20050026220 Isolation and mobilization of stem cells expressing vegfr-1 |
| 02/03/2005 | US20050025806 A silicone support of methylvinylsiloxane polymer including a fumed silca reinforcement filler; growth and/or reproduction-associated drug, derivative or analogue and carrier; each implant of insufficient size and/or payload for the predetermined threshold blood level of indicated drug; high-speed |
| 02/03/2005 | US20050025751 Increased or reduced expression of tumor necrosis factors or interleukins; antiinflammatory agents; autoimmune diseases |
| 02/03/2005 | DE10329955A1 Verwendung eines hydroalkoholischen Extrakts aus Bauhinia zur Herstellung einer Zubereitung Use of a hydroalcoholic extract of Bauhinia for producing a preparation |
| 02/03/2005 | DE10057976B4 Verfahren zur Herstellung von Pektinhydrolyseprodukten A process for producing pectin hydrolysis products |
| 02/03/2005 | CA2770493A1 Cyclohexanecarboxylic acid compound |
| 02/03/2005 | CA2533402A1 A1 adenosine receptor antagonists |
| 02/03/2005 | CA2531491A1 Agonist polypeptide of receptor for zot and zonulin |
| 02/03/2005 | CA2528586A1 Cyclohexanecarboxylic acid compound |
| 02/02/2005 | EP1502949A1 Antimicrobial polypeptide and utizliation thereof |
| 02/02/2005 | EP1502916A1 Piperidine derivatives having ccr3 antagonism |
| 02/02/2005 | EP1502600A1 Use of botulinum toxin for treating smooth muscle disorders |
| 02/02/2005 | EP1502590A1 Heterocyclic oxime derivatives, process for their preparation and use thereof in the treatment of type II diabetes |
| 02/02/2005 | EP1501936A2 Cytokine protein family |
| 02/02/2005 | EP1501930A2 Oligomeric compounds for the modulation hif-1alpha expression |
| 02/02/2005 | EP1501919A1 Soya cell strains with high isoflavone content |
| 02/02/2005 | EP1501862A2 Novel analogues of glucose-dependent insulinotropic polypeptide |
| 02/02/2005 | EP1501835A2 2-(quinolonyl)-fused heterocycles as androgen receptor modulators |
| 02/02/2005 | EP1501834A1 Triaryl-oxy-aryl-spiro-pyrimidine-2, 4, 6-trione metalloproteinase inhibitors |
| 02/02/2005 | EP1501833A1 N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 02/02/2005 | EP1501827A2 Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acid and their use as protease inhibitors |
| 02/02/2005 | EP1501826A2 Substituted indoles as alpha-1 agonists |
| 02/02/2005 | EP1501819A1 Estrogen receptor modulators |
| 02/02/2005 | EP1501817A1 Imidazolinylmethyl aralkylsulfonamides |
| 02/02/2005 | EP1501813A2 Benzothiadiazepine derivatives, processes for their preparation and pharmaceutical compositions containing them |
| 02/02/2005 | EP1501809A1 Triazole derivatives as tachykinin receptor antagonists |
| 02/02/2005 | EP1501808A1 Tachykinin receptor antagonists |
| 02/02/2005 | EP1501807A1 Sulfonylquinoxalone acetamide derivatives and related compounds as bradykinin antagonists |
| 02/02/2005 | EP1501803A2 Tetrahydropyranyl cyclopentyl tetrahydroisoquinoline modulators of chemokine receptor activity |
| 02/02/2005 | EP1501801A1 2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses as vla-4 inhibitors |
| 02/02/2005 | EP1501800A1 Bombesin antagonists |
| 02/02/2005 | EP1501794A1 Thiazolidinones and the use thereof as polo-like kinase inhibitors |
| 02/02/2005 | EP1501787A1 N-biphenylmethyl aminocycloalkanecarboxamide derivatives with a substiituent on the methyl useful as bradykinin antagonists |
| 02/02/2005 | EP1501545A2 Use of tnfalpha antibodies and another drug |
| 02/02/2005 | EP1501538A2 Use of alpha-s2 casein precursor-derived peptides |
| 02/02/2005 | EP1501526A1 Curcumin for the prevention and/or treatment of tissue damage |
| 02/02/2005 | EP1501525A1 Method for producing preparations rich in tocotrienol |
| 02/02/2005 | EP1501515A1 Triaryl-oxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 02/02/2005 | EP1501514A2 Protein kinase modulators and methods of use |
| 02/02/2005 | EP1501512A2 4-azasteroid derivatives as androgen receptor modulators |
| 02/02/2005 | EP1501508A1 Inhibitors of histone deacetylase |
| 02/02/2005 | EP1501506A1 Fxr agonists for hepatoprotection and treatment of cholestasis |
| 02/02/2005 | EP1501504A1 1-substituted imidazole derivatives as nos inhibitors |
| 02/02/2005 | EP1501498A1 Pharmaceutical composition comprising a lipase inhibitor and glucomannan |
| 02/02/2005 | EP1501495A1 Use of pleuromutilins for the treatment of disorders caused by helicobacter pylori |
| 02/02/2005 | EP1501488A1 USE OF GABA sb B /sb RECEPTOR POSITIVE MODULATORS IN GASTRO-INSTESTINAL DISORDERS |
| 02/02/2005 | EP1501482A1 Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease |
| 02/02/2005 | EP1501467A2 Heterocyclo inhibitors of potassium channel function |
| 02/02/2005 | EP1379257A4 Prodrugs of anticancer agents employing substituted aromatic acids |
| 02/02/2005 | EP1303521B1 Tetrahydro-heterocycloazepinyl pyrimidine derivatives |